U.S. to remove mercury preservative from flu shots following RFK Jr. vaccine panel vote 

U.S. to remove mercury preservative from flu shots following RFK Jr. vaccine panel vote 


U.S. Health and Human Services (HHS) Secretary Robert F. Kennedy Jr., speaks with Agriculture Secretary Brooke Rollins and Senator Roger Marshall (R-KS) ahead of a roundtable event as part of the “Make America Healthy Again” (MAHA) agenda, on Capitol Hill in Washington, D.C., U.S., July 15, 2025.

Ken Cedeno | Reuters

The Department of Health and Human Services on Wednesday said it will officially remove the mercury-based preservative thimerosal from all flu shots distributed in the U.S. – even though there is no evidence of harm from the ingredient. 

While few jabs still contain thimerosal, the move eliminates a vaccine option for Americans and is a win for the anti-vaccine movement, which has long targeted the ingredient.

HHS Secretary Robert F. Kennedy Jr. formally adopted a June recommendation from a key government vaccine panel, called the Advisory Committee on Immunization Practices, or ACIP, against influenza shots containing thimerosal. Earlier that month, Kennedy gutted that panel and restacked it with new members, including some widely known anti-vaccine activists. 

The decision affects roughly 4% to 5% of the U.S. flu vaccine supply. That includes some multi-dose forms of Sanofi‘s Fluzone and two shots from biotech company CSL Seqirus. The rest of the nation’s flu shots were thimerosal-free during the last season of the virus, according to CDC data.

Vaccine manufacturers have confirmed that they have the capacity to replace multi-dose vials containing mercury, HHS said. That will ensure that the flu vaccine for adults and a government program that provides shots to uninsured and underinsured children won’t be interrupted, the agency added. 

Still, health experts have said that eliminating thimerosal-containing flu shots as an option for Americans could lead to fewer people receiving jabs.

The move also reinforces longstanding, unfounded fears that the substance can lead to developmental disabilities, such as autism. Kennedy’s vaccine skepticism comes full circle with ACIP’s vote: A decade before stepping into his current role, he published a book that called for the removal of thimerosal from shots and linked it to developmental disorders.

“After more than two decades of delay, this action fulfills a long-overdue promise to protect our most vulnerable populations from unnecessary mercury exposure,” Kennedy said in a release, urging global health authorities to follow suit. 

More than 40 studies over several decades have found no link between thimerosal and developmental delays. Thimerosal has been widely used for decades as a preservative to prevent the growth of harmful bacteria in several medicines and vaccines with multiple doses.

HHS said other recommendations from the panel’s meeting in June are still under review.



Source

OpenEvidence, the ‘ChatGPT for doctors,’ doubles valuation to  billion
Health

OpenEvidence, the ‘ChatGPT for doctors,’ doubles valuation to $12 billion

A startup widely known as “ChatGPT for doctors” raised a new funding round that values the company at $12 billion. OpenEvidence, based in Miami, Florida, closed a $250 million financing, led by Thrive Capital and DST, the company told CNBC. The startup first raised outside capital in February, when it reeled in $75 million from […]

Read More
Another alliance of health care and AI signals why pharma stocks should be back in favor
Health

Another alliance of health care and AI signals why pharma stocks should be back in favor

Bristol Myers Squibb and Microsoft ‘s new partnership aimed at accelerating early detection of lung cancer marks the latest way health care and artificial intelligence are rapidly intersecting. Bristol Myers said on Tuesday it will work with Microsoft’s AI-powered radiology platform to develop and launch imaging algorithms. These new tools, which can be used to […]

Read More
Drug pricing, patent losses and deals: Here’s what pharma execs see ahead in the industry
Health

Drug pricing, patent losses and deals: Here’s what pharma execs see ahead in the industry

US President Donald Trump arrives for an announcement in the Roosevelt Room of the White House in Washington, DC, US, on Friday, Dec. 19, 2025. Will Oliver | Bloomberg | Getty Images Drug pricing. Looming patent cliffs. Dealmaking. The first year of Trump 2.0. Those are among the themes that dominated conversations last week as drugmakers […]

Read More